New Treatment for Brain Lymphoma (R-PMDT)
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination drug treatment called R-PMDT for patients newly diagnosed with a type of lymphoma that starts in the brain (PCNSL). The goal is to see if this regimen can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma)
- Your blood cell counts are healthy enough: white blood cells ≥1.0×10⁹/L and platelets ≥75×10⁹/L
- Your liver and kidney function are adequate (specific blood test results within acceptable ranges)
- Your heart pumps well, with ejection fraction ≥55% (checked by heart ultrasound)
- You have not had prior cancer treatment except possibly steroids
- You do not have uncontrolled heart disease, active infections, or active hepatitis B/C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial studies a treatment plan for people with newly diagnosed non-Hodgkin lymphoma that has spread to the brain and covering tissues (meninges). It combines medicines given through the bloodstream with immunotherapy placed into the fluid around the brain (CSF) to improve control of the lymphoma.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
This trial compares two treatment combinations for newly diagnosed primary CNS lymphoma (PCNSL), a rare type of brain lymphoma. It tests whether adding a drug called PD-1 (a type of immunotherapy that helps your immune system fight cancer) to the standard chemotherapy (R-MA) improves outcomes compared to R-MA alone. Participating gives access to a novel combination that may be more effective, though it involves extra monitoring and possible immune-related side effects.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
Hear when a new Primary Central Nervous System (CNS) Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.